Dose escalation study to assess the safety and tolerability of sub-conjunctival injections of XG-102 in patients with post-surgery or post-traumatic intraocular inflammation

Trial Profile

Dose escalation study to assess the safety and tolerability of sub-conjunctival injections of XG-102 in patients with post-surgery or post-traumatic intraocular inflammation

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Sep 2014

At a glance

  • Drugs Brimapitide (Primary)
  • Indications Ocular inflammation
  • Focus Adverse reactions
  • Sponsors Xigen
  • Most Recent Events

    • 22 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top